SecBot SecBot
8-K ·Filed Aug 4, 2026

JNJ

JOHNSON & JOHNSON
NEUTRAL
Impact 2/10
Horizonimmediate Processed3mo ago SEC0000200406-26-000167
8-K context-dependent: Items 5.02
Actionable Insight • Neutral

Monitor for any strategic shifts in Innovative Medicine under Cavanaugh's leadership, but no near-term trading catalyst from this filing.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$254.93
T+0 close · Aug 4, 2026 · via day close
Latest settled
+5.41%
T+60 · $268.73
Vs SPY
+5.63%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Aug 4 $254.93entry
  2. T+1 · 3mo ago +1.04%α +1.24% · $257.59
  3. T+5 · 3mo ago +1.91%α +2.01% · $259.80
  4. T+20 · 3mo ago +6.38%α +7.62% · $271.19
  5. T+60 · 20d ago +5.41%α +5.63% · $268.73
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Johnson & Johnson announced the retirement of Jennifer Taubert, EVP and Worldwide Chairman of Innovative Medicine, effective September 1, 2026, with Tom Cavanaugh appointed as her successor. This is a routine leadership transition at a mega-cap pharmaceutical company with a named internal replacement, carrying no material financial impact.

Key Facts

  • Jennifer Taubert to retire as EVP, Worldwide Chairman, Innovative Medicine effective September 1, 2026.
  • Tom Cavanaugh appointed as successor, effective September 1, 2026, and will join the Executive Committee.
  • Taubert had a 21-year tenure at J&J; under her leadership, Innovative Medicine grew to more than $60 billion in annual revenue.
  • Cavanaugh has nearly 30 years of biopharma experience, including 9 years at J&J and prior roles at Celgene.

Financial Impact

No financial impact disclosed; routine executive succession at a $617.8B market cap company.

Risk Factors

  • No material risks identified from this filing.

Market Snapshot

Price
$252.81
Volume
100
Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
71% bullish (31 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000200406-26-000167
Document: pressrelease08042026.htm0000200406-26-000167
Document: 0000200406-26-000167-index-headers.html0000200406-26-000167
Document: 0000200406-26-000167-index.html0000200406-26-000167
Document: 0000200406-26-000167.txt0000200406-26-000167

Track record

21 reports on JNJ

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+60. Best: +13.24% at T+60 after the May 13, 2026 report. 6 of 6 went positive at some point.

Filters
  1. Nov 16, 2026today Institutional Cluster Mixed 3/10 Entry $289.75 Now $285.75 −1.38% settles Feb 12
  2. Nov 12, 20264d ago 144 Neutral 2/10 Entry $283.52 Now $285.75 +0.79% settles Feb 10
  3. Oct 13, 20264w ago 8-K Mixed 6/10 Entry $248.61 Now $285.75 +14.94% settles Jan 8
  4. Sep 30, 20266w ago Court Ruling Bullish 6/10 Entry $258.66 Now $285.75 +10.47% settles Dec 28
  5. Sep 24, 20267w ago Court Ruling Neutral 3/10 Entry $271.22 Now $285.75 +5.36% settles Dec 21
  6. Sep 9, 20269w ago Court Ruling Neutral 1/10 Entry $266.35 Now $285.75 +7.28% settles Dec 4
  7. Aug 18, 202612w ago Insider Cluster Neutral 2/10 Entry $273.41 to $283.52 Now $285.75 +4.51% ▲ +3.70% +5.25% vs SPY
  8. Aug 14, 202613w ago Insider Cluster Neutral 2/10 Entry $262.37 to $280.78 Now $285.75 +8.91% ▲ +7.02% +9.96% vs SPY
  9. Aug 7, 202614w ago Insider Cluster Neutral 3/10 Entry $261.81 to $266.17 Now $285.75 +9.14% ▲ +1.67% +4.08% vs SPY
  10. Aug 7, 202614w ago Court Ruling Bearish 4/10 Entry $261.81 to $266.17 Now $285.75 −9.14% ▼ −1.67% −4.08% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens Wed (12h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 4, 2026